CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis

@inproceedings{Gerdes2016CTLA4AI,
  title={CTLA4 as Immunological Checkpoint in the Development of Multiple Sclerosis},
  author={Lisa Ann Gerdes and Kathrin Held and Eduardo Beltr{\'a}n and Carola Berking and Joerg Christoph Prinz and Andreas Junker and Julia K. Tietze and B Ertl-Wagner and Andreas M. Straube and Tania Kuempfel and Klaus Dornmair and Reinhard Hohlfeld},
  booktitle={Annals of neurology},
  year={2016}
}
We investigated a patient who developed multiple sclerosis (MS) during treatment with the CTLA4-blocking antibody ipilimumab for metastatic melanoma. Initially he showed subclinical magnetic resonance imaging (MRI) changes (radiologically isolated syndrome). Two courses of ipilimumab were each followed by a clinical episode of MS, 1 of which was accompanied by a massive increase of MRI activity. Brain biopsy confirmed active, T-cell type MS. Quantitative next generation sequencing of T-cell… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 12 times over the past 90 days. VIEW TWEETS
6 Citations
26 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Similar Papers

Loading similar papers…